Patents Examined by Raymond Covington
  • Patent number: 9802951
    Abstract: The present invention relates to a novel chemical compound for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.
    Type: Grant
    Filed: July 25, 2013
    Date of Patent: October 31, 2017
    Assignee: Tapestry Pharmaceuticals, Inc.
    Inventors: James D. McChesney, Gilles H. Tapolsky, David Lloyd Emerson, John Marshall, Michael Kurman, Manuel R. Modiano
  • Patent number: 9428498
    Abstract: The present invention relates to compounds which are inhibitors of SSAO activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases, immune disorders and the inhibition of tumor growth.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: August 30, 2016
    Assignee: Proximagen Limited
    Inventors: Max Espensen, Lee Patient, David Evans, Edward Savory, Iain Simpson
  • Patent number: 9422303
    Abstract: Provided are compositions, methods of making the compositions, and methods of using the compositions. The compositions can be provided as pharmaceutical preparations for use in disease treatment, such as cancer therapy. The compositions include novel pharmaceutical preparations which contain effective concentrations of a chemical compound. One compound used is 10H-1,3-Dioxolo[4,5-g]pyrano[3?,4?:6,7]indolizino[1,2-b]quinoline-8,11(7H,12H)-dione, 7-ethyl-7-hydroxy-, (S)-. The invention also provides methodologies for preparing pharmaceutical preparations for use in intravenous and oral pharmaceutical preparations that contain drug compounds that are difficult to dissolve in water.
    Type: Grant
    Filed: October 31, 2011
    Date of Patent: August 23, 2016
    Assignee: Health Research, Inc.
    Inventors: Fengzhi Li, Xiang Ling, Shousong Cao
  • Patent number: 9359376
    Abstract: The present invention relates to the synthesis and application of novel chiral/achiral substituted methyl formyl reagents to modify pharmaceutical agents and/or biologically active substances to modify the physicochemical, biological and/or pharmacokinetic properties of the resulting compounds from the unmodified original agent.
    Type: Grant
    Filed: April 9, 2012
    Date of Patent: June 7, 2016
    Assignee: SPHAERA PHARMA PTE. LTD
    Inventors: Sundeep Dugar, Dinesh Mahajan, Frank Peter Hollinger
  • Patent number: 9359318
    Abstract: Process for the synthesis of 2,5-furandicarboxylic acid through the oxidation of -hydroxymethylfurfural in a flow of oxygenor a compound containing oxygen, catalyzed by a supported catalyst containing a metal of the platinum group, carried out in aqueous solution in which the pH is maintained higher than 7 and lower than 12 through the addition of a weak base.
    Type: Grant
    Filed: August 4, 2011
    Date of Patent: June 7, 2016
    Assignee: Novamont S.p.A.
    Inventors: Giampietro Borsotti, Francesca Digioia
  • Patent number: 9309210
    Abstract: The present invention relates to a novel crystalline ethyl acetate solvate form of cabazitaxel or 4?-acetoxy-2?-benzoyloxy-5?,20-epoxy-1?-hydroxy-7?,10?-dimethoxy-9-oxo-11-taxen-13?-yl(2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate and process for preparing the same.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: April 12, 2016
    Assignee: AVENTIS PHARMA S.A.
    Inventors: Eric Didier, Nicolas Tremaudeux, Lionel Zaske
  • Patent number: 9303004
    Abstract: Disclosed is a method of crystallizing a taxane comprising combining the taxane and methylene chloride to obtain a solution and adding an anti-solvent to the solution to obtain a crystalline taxane, wherein the anti-solvent is selected from the group consisting of hexane and heptane.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: April 5, 2016
    Assignee: Phyton Holdings, LLC
    Inventors: James H. Johnson, T. G. Sambandam, Barry J. Hand, Christopher D. Howe, Roland R. Franke, Brian A. Bucher, John S. Juchum, Rex T. Gallagher, Marc A. Plante, Edward M. Desimone, III, Dong S. Yang
  • Patent number: 9296686
    Abstract: The present invention relates to the preparation of (R)—N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and (S)—N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide.
    Type: Grant
    Filed: August 25, 2014
    Date of Patent: March 29, 2016
    Assignee: ARDEA BIOSCIENCES, INC.
    Inventors: Andreas Maderna, Jean Michel Vernier
  • Patent number: 9296673
    Abstract: The present invention relates to a new process for the preparation of 6-hydroxy-5-arylbicyclo[2.2.2]octan-2-one compounds of the formula (II); which may subsequently be further transformed to compounds of the formula (I): The present invention further relates to novel compounds as such, which compounds are useful intermediates in the above process.
    Type: Grant
    Filed: October 19, 2011
    Date of Patent: March 29, 2016
    Assignee: ACTELION PHARMACEUTICALS LTD.
    Inventors: Stefan Abele, Jacques-Alexis Funel
  • Patent number: 9296716
    Abstract: Non ligand binding pocket antagonists for the human androgen receptor. The androgen receptor (AR) is a member of the Nuclear Receptor (NR) family and its role is to modulate the biological effects of the endogenous androgens, testosterone (tes) and dihydrotestosterone (DHT). Synthetic androgens and anti-androgens have therapeutic value in the treatment of various androgen dependent conditions, from regulation of male fertility to prostate cancer. Current treatment of prostate cancer (PCa) typically involves administration of ‘classical’ antiandrogens, competitive inhibitors of natural AR ligands, DHT and tes, for the ligand binding pocket (LBP) in the C-terminal ligand binding domain (LBD) of the AR. However, prolonged LBP-targeting can often lead to androgen resistance and alternative therapies and therapeutic strategies are urgently required. Disclosed herein are a class of non-steroidal, small molecule AR antagonists which inhibit the transcriptional activity of the AR by non LBP-mediated modulation.
    Type: Grant
    Filed: November 23, 2012
    Date of Patent: March 29, 2016
    Assignee: THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIV. TRINITY OF QUEEN ELIZABETH NEAR DUBLIN
    Inventors: David George Lloyd, Darren Fayne, Mary Jane Meegan, Miriam Carr, Gemma Karena Kinsella, Laura Caboni, Wiliam Nicholas Jagoe, Billy Egan, Fernando Blanco, D. Clive Williams
  • Patent number: 9284327
    Abstract: The present invention provides a method for the preparation of orally available pentacyclic taxane compounds, as well as intermediates useful in their preparation.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: March 15, 2016
    Assignee: GFV, LLC
    Inventors: John K. Thottathil, Raymond P. Warrell
  • Patent number: 9278086
    Abstract: The invention relates to compounds, methods, uses, compositions, combinations, kits and packages for the prevention and/or treatment of parasite infection (e.g., Plasmodium parasites) and/or disease (e.g., malaria) based on uses of (a) cystamine, cysteamine, and analogs, derivatives, prodrugs, precursors thereof; an agent capable of inducing their production; and/or salts thereof, and (b) artemisinin and functional derivative, analog, conjugate, metabolite, prodrug or precursor thereof, and/or salts thereof.
    Type: Grant
    Filed: July 16, 2014
    Date of Patent: March 8, 2016
    Assignee: The Royal Institution for the Advancement of Learning/McGill University
    Inventors: Philippe Gros, Gundula Min-Oo, Anny Fortin
  • Patent number: 9266853
    Abstract: An object of the present invention is to provide a compound that is useful as an orally available anti-HCV agent. The present invention relates to a compound represented by formula (1) or a pharmaceutically acceptable salt thereof. This compound has an anti-HCV activity and is useful as a medicine.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: February 23, 2016
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Yasunori Kohchi, Kimitaka Nakama, Susumu Komiyama, Fumio Watanabe
  • Patent number: 9266852
    Abstract: Disclosed is a daidzein derivative as represented by formula (I), or pharmaceutically acceptable salt thereof. Compared to the daidzein in the prior art, the daidzein derivative hydrochloride, in particular to the 7-O—N,N-diethyl-aminoacetyl daidzein hydrochloride, prepared by the daidzein derivative of the present invention, has better solubility and effect for treating cardiovascular diseases.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: February 23, 2016
    Assignee: Anhui Biochem Bio-Pharmaceutical Co., Ltd
    Inventors: Jun Bai, Caiyue Shen, Shigao Hu
  • Patent number: 9259412
    Abstract: The present invention relates to modafinil or derivatives thereof as a medicine for the treatment of vascular diseases or KCa3.1 channel (Ca activated K channel) mediated diseases and a novel use of the same. More specifically, the present invention relates to a pharmaceutical composition for the prevention or treatment of vascular diseases or KCa3.1 channel-mediated diseases comprising modafinil or a derivative of modafinil, or pharmaceutically acceptable salts thereof which relax blood vessels and inhibit KCa3.1 channel currents by increasing intracellular cAMP, a method for treating vascular diseases or KCa3.1 channel-mediated diseases using the composition and a health functional food composition for the prevention or improvement of vascular diseases or the KCa3.1 channel-mediated diseases comprising modafinil or a modafinil derivative compound, or sitologically acceptable salts thereof.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: February 16, 2016
    Assignee: EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION
    Inventors: Suk Hyo Suh, Jae Chul Jung, Sei Kwan Oh
  • Patent number: 9260406
    Abstract: Specifically useful stereoisomers of 1,3-dioxane derivatives are described and their use in the treatment of a disease or condition dependent on PPAR modulation, such as diabetes, cancer, inflammation, neurodegenerative disorders and infections as well as their use in the treatment of a disease related to TP, such as cardiovascular diseases.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: February 16, 2016
    Assignee: Evolva SA
    Inventors: Alexandra Santana Sorensen, Jean-Philippe Meyer, Peteris Alberts, Prathama S. Mainkar, Melya Hughes Crameri
  • Patent number: 9242953
    Abstract: The present disclosure relates to processes for preparing dronedarone or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: August 26, 2014
    Date of Patent: January 26, 2016
    Assignee: Gilead Sciences, Inc.
    Inventors: Johann Chan, Justin Vitale
  • Patent number: 9242952
    Abstract: A method to produce 5-hydroxymethylfurfural (HMF) is described in which a reactant including cellulose, lignocellulose, or a combination thereof, in a reaction mixture of a polar, aprotic solvent and an acid is reacted for a time, at a temperature, and at a hydrogen ion concentration wherein at least a portion of the cellulose or lignocellulose present in the reactant is converted to HMF. The reaction mixture is initially substantially devoid of water. As the reaction proceeds, dehydration of intermediates causes the water concentration in the reaction mixture to rise to no more than about 0.2 wt % water.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: January 26, 2016
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: James A. Dumesic, George W. Huber, Ronen Weingarten
  • Patent number: 9238672
    Abstract: The invention is directed to a method to reduce a C—C double bond of an enone of a steroidal compound to produce a mixture of ? ketone product and ? ketone product, comprising treating a solution or suspension of the steroidal compound in a solvent with hydrogen gas in the presence of a catalyst and a substituted pyridine.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: January 19, 2016
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Brian C. Austad, Andre Lescarbeau, Lin-Chen Yu
  • Patent number: 9233961
    Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as Leishmaniasis, Human African Trypanosomiasis and Chagas disease.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: January 12, 2016
    Assignees: Novartis AG, University of Washington through its Center for Commercialization
    Inventors: Arnab Kumar Chatterjee, Fang Liang, Casey Jacob Nelson Mathison, Pranab Kumar Mishra, Valentina Molteni, Advait Suresh Nagle, Frantisek Supek, Liying Jocelyn Tan, Agnes Vidal, Michael Herman Gelb, Frederick Simmons Buckner, Hari Babu Tatipaka, Neil Richard Norcross, John Robert Gillespie